Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis.
Medicine (Baltimore)
; 98(46): e17860, 2019 Nov.
Article
en En
| MEDLINE
| ID: mdl-31725627
ABSTRACT
BACKGROUND:
Liraglutide is a novel, long-acting glucagon-like peptide-1 (GLP-1) analogue used to treat type 2 diabetes mellitus. However, the cardiovascular safety and benefits of liraglutide treatment on type 2 diabetes patients remain in debate. In this study, we aimed to examine the overall cardiovascular outcomes of liraglutide in patients with type 2 diabetes.METHODS:
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.RESULTS:
Eight studies fulfilled the eligibility criteria for inclusion and 14,608 patients were analyzed in this systematic review and meta-analysis. We found patients in the liraglutide group had a lower risk of major cardiovascular events (MACE) (RRâ=â0.89, 95% CI 0.82-0.96, Pâ=â.002), acute myocardial infarction (AMI) (RRâ=â0.85, 95% CI 0.74-0.99, Pâ=â.036), all-cause death (RRâ=â0.84, 95% CI 0.74-0.96, Pâ=â.009), and cardiovascular death (RRâ=â0.77, 95% CI 0.65-0.91, Pâ=â.002) than all comparator groups. However, liraglutide treatment did not decrease incidence of stroke (RRâ=â0.86, 95% CI 0.70-1.04, Pâ=â.124). But among the MACE subgroups analysis, a significant reduction of MACE with liraglutide was only observed in placebo-controlled trials (RRâ=â0.89, 95% CI 0.83-0.96, Pâ=â.004) but not in studies concerning other comparators (RRâ=â0.58, 95% CI 0.29-1.16, Pâ=â.122).CONCLUSIONS:
In conclusion, our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and cardiovascular death among patients with type 2 diabetes.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades Cardiovasculares
/
Diabetes Mellitus Tipo 2
/
Liraglutida
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2019
Tipo del documento:
Article